Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
24.85
+0.55 (2.26%)
Jan 22, 2026, 3:03 PM EST - Market open
Elanco Animal Health Employees
As of December 31, 2024, Elanco Animal Health had 9,450 total employees, including 9,000 full-time and 450 part-time employees. The number of employees decreased by 350 or -3.57% compared to the previous year.
Employees
9,450
Change (1Y)
-350
Growth (1Y)
-3.57%
Revenue / Employee
$485,820
Profits / Employee
$3,810
Market Cap
12.35B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 9,450 | -350 | -3.57% | 9,000 | 450 |
| Dec 31, 2023 | 9,800 | 60 | 0.62% | 9,300 | 500 |
| Dec 31, 2022 | 9,740 | 740 | 8.22% | 9,000 | 740 |
| Dec 31, 2021 | 9,000 | -1,200 | -11.76% | 9,000 | 0 |
| Dec 31, 2020 | 10,200 | 4,120 | 67.76% | 10,200 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 36,830 |
| Viatris | 32,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Amneal Pharmaceuticals | 8,300 |
| Neurocrine Biosciences | 1,800 |
| Alkermes | 1,800 |
| Hims & Hers Health | 1,637 |
| United Therapeutics | 1,305 |
ELAN News
- 7 hours ago - Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement - PRNewsWire
- 8 days ago - Elanco Animal Health Incorporated (ELAN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Elanco Animal Health: Innovation-Led Growth Model Plus Credible Deleveraging Path - Seeking Alpha
- 16 days ago - Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 22 days ago - Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis - PRNewsWire
- 5 weeks ago - Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs - PRNewsWire
- 5 weeks ago - Jim Cramer Praises Elanco Animal Health: 'They've Turned That Company Around' - Benzinga
- 5 weeks ago - Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript - Seeking Alpha